stockrow
Friday 6 November 2026
Export NEPH’s income statement to Excel — free account
Nephros Inc.
NEPH Healthcare Medical Instruments & Supplies
Nephros Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 32.7% from fiscal 2024.
- Revenue
- +18.0%
- EPS
- +66.7%
- Free cash flow
- −251.5%
Quarter to September 2026, against a year earlier
2.82
0.27
−8.74%
Follow NEPH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.10 | 22.91 | 45.29 | 46.12 |
+8 more quarters Free account |
P/S ratio |
1.87 | 1.87 | 1.66 | 2.76 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 34.07 | |
P/Operating CF |
(268.68) | 56.92 | (18.99) | 225.16 | |
P/B ratio |
3.21 | 3.24 | 2.97 | 5.08 | |
Price to Tangible BV |
3.55 | 3.60 | 3.35 | 5.78 | |
EV/Sales |
1.66 | 1.64 | 1.45 | 2.47 | |
EV/EBITDA |
18.39 | 19.32 | 34.53 | 36.10 | |
EV/Operating CF |
(39.30) | (51.54) | (79.68) | 28.20 | |
EV/FCF |
(34.55) | (43.34) | (58.62) | 30.52 | |
Quick Ratio |
3.37 | 2.63 | 2.98 | 2.82 | |
Current Ratio |
5.50 | 4.07 | 4.55 | 4.06 | |
Net Debt/EBITDA |
(8.58) | (3.78) | (32.40) | (108.00) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.51 | 1.48 | 1.50 | 1.51 | |
Operating CF/Net income |
(0.29) | 0.57 | (11.94) | 3.71 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | 1,213.00 | — | — | |
Research and Development Expense of Revenue |
5.89% | 6.08% | 6.64% | 8.35% | |
Selling, General and Administrative Expense of Revenue |
43.13% | 40.19% | 48.37% | 48.97% | |
Intangible Assets out of Total Assets |
0.00 | 0.08 | 0.09 | 0.09 | |
Share Based Compensation of Revenue |
1.07% | 1.01% | 1.15% | 1.67% | |
Graham Net Nets |
0.26 | 0.25 | 0.26 | 0.15 | |
Graham Number |
2.14 | 1.97 | 1.22 | 1.51 | |
Earnings Yield |
4.74% | 4.36% | 2.21% | 2.17% | |
Free Cash Flow Yield |
(2.57%) | (2.03%) | (1.49%) | 2.94% | |
Revenue per Share |
0.52 | 0.55 | 0.49 | 0.45 | |
Operating CF per Share |
(0.01) | 0.06 | (0.16) | 0.02 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.01) | 0.06 | (0.16) | 0.02 | |
Cash per Share |
0.42 | 0.43 | 0.38 | 0.51 | |
Shareholders Equity per Share |
1.16 | 1.10 | 1.00 | 0.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.16 | 1.10 | 1.00 | 0.96 | |
Free Cash Flow |
(0.15) | 0.68 | (1.67) | 0.23 | |
Working Capital |
10.85 | 10.25 | 8.97 | 8.46 | |
Net Current Asset Value |
10.50 | 9.79 | 8.40 | 7.78 | |
EV/EBIT |
19.55 | 20.75 | 40.96 | 40.48 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
22.04 | 23.61 | 46.88 | 45.19 | |
| Other line items | |||||
Average Receivables |
3.12 | 3.07 | 3.10 | 2.10 | |
Average Payables |
0.89 | 1.30 | 1.01 | 0.78 | |
Average Inventory |
3.85 | 3.39 | 2.79 | 2.92 | |
Average Assets |
14.28 | 14.01 | 12.79 | 12.43 | |
Average Common Equity |
11.28 | 10.78 | 10.00 | 9.39 |
Columns are period end dates · fundamentals updated 5 Nov 2026